• 7/12/2019

A Statement from Our CEO

“We continue to be disappointed at the allegations made by the Federal Trade Commission. We wholeheartedly share the FTC’s focus on lowering healthcare costs, and we have achieved significant reductions with e-prescribing for many years. However, the FTC’s complaint makes significant factual errors about Surescripts’ business and mischaracterizes the economic realities of the e-prescribing market. As such, our Counsel has filed a Motion to Dismiss based on the facts and merits of the case.

It is important to highlight that while the cost of American healthcare overall continues to rise, Surescripts has reduced the cost of e-prescribing by 70% since 2009, a goal we will continue to focus on as a critical part of our business. And, since 2016 we have driven a 64% improvement in the accuracy of the more than five million electronic prescriptions we process each day. There is no question that e-prescribing has brought enormous value to patients and clinicians alike through innovations in accuracy, safety and convenience.

We take seriously our role in helping serve patients and the people who care for them, and we are confident that our business practices support that goal. And, our business continues to evolve, including our removal of loyalty provisions from our agreements with pharmacies.

Our number one focus remains serving our customers who make up the Surescripts Network Alliance. Together we are leading the important transition to NCPDP SCRIPT standard v2017071 and the implementation of electronic prescribing of controlled substances to digitize prescriptions that help address the opioid crisis. We are also dedicated to further increasing prescription accuracy and driving innovations that promote ongoing decreases in the price of electronic prescribing.”

- Tom Skelton, Chief Executive Officer, Surescripts

 
  • 4/24/2019

A Statement from Our CEO

“Surescripts is very disappointed at the allegations made today by the Federal Trade Commission. For more than 18 years, we have operated fairly in an innovative and dynamic marketplace to increase patient safety, lower costs and ensure quality healthcare.

Surescripts pioneered the use of two-sided networks that enable the safe and secure exchange of patient health information. Since 2009, Surescripts has reduced the price of electronic prescribing by 70%. And, in just the last three years, we drove a 64% improvement in the accuracy of the more than 5 million electronic prescriptions we process each day.

We are making an important change to our e-prescribing business agreements with pharmacies by removing the loyalty provisions in those contracts. This step addresses one of the FTC’s chief concerns while reflecting the current dynamics of the healthcare industry and the state of electronic prescribing today.

Surescripts has been cooperating with the FTC throughout its investigation, and we remain focused on meeting our customers’ needs. We take seriously our role in helping medical professionals better serve patients, who are the ultimate beneficiaries of our nationwide health information network.”

- Tom Skelton, Chief Executive Officer, Surescripts

 

To learn more about Surescripts, visit Surescripts.com